Nerve growth factor suppresses the tumoral phenotype of human prolactinomas

Cristina Missale, Sandra Sigala, Chiara Fiorentini, Alessandra Finardi, Marco Losa, Massimo Giovanelli, PierFranco Spano

Research output: Contribution to journalArticlepeer-review

Abstract

We summarize here our data showing that various phenotypical characteristics distinguish prolactinoma cell lines obtained from responder and nonresponder patients, as defined by their responses to bromocriptine administration. Nonresponder cell lines have a higher degree of malignancy than responder cells and do not express D2 receptors for dopamine. Both cell lines express NGF receptors. Exposure of the most malignant nonresponder cell lines to NGF, both in vitro and when transplanted in vivo in nude mice, results in their differentiation into the responder phenotype reexpressing D2 receptors. Sequential administration of NGF and bromocriptine thus may be a promising therapy for patients refractory to bromocriptine.

Original languageEnglish
Pages (from-to)240-244
Number of pages5
JournalHormone Research
Volume47
Issue number4-6
Publication statusPublished - Apr 1997

Keywords

  • Bromocriptine
  • Differentiation
  • Dopamine receptors
  • Prolactin

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Nerve growth factor suppresses the tumoral phenotype of human prolactinomas'. Together they form a unique fingerprint.

Cite this